LDS/Medical Tests/CDH1 Gene Mutation Analysis

CDH1 Gene Mutation Analysis

Located on chromosome number 16, E-cadherin is a calcium ion dependent adhesion molecule and plays a major role in development and maintenance of epithelial cell integrity. Mutations of this gene include insertions, deletions, splice site, nonsense and exonic mutations. Loss of gene expression due to any of above mutations lead to rare but aggressive malignancies like HDGC (Hereditary diffuse gastric cancer) and LBC (Lobular breast cancer), also known as Lobular carcinoma in situ.

Hereditary diffuse gastric cancer (HDGC) is inherited as autosomal dominant condition and affected patients have a marked predisposition for gastric cancer. In contrast to other types of gastric cancer, HDGC presents mostly as a flat surface growth over the lining of stomach. Patients frequently present with pain, nausea, vomiting, dysphagia, anorexia, and weight loss. In later stages patients may present with hepatomegaly, ictrus, ascites, lymphadenopaty and pathological bone fractures. Orofacial cleft has also been documented as a feature of HDGC in several individuals.

Women with this CDH1 mutations are at high risk of developing lobular carcinoma of the breast (LBC). During initial stages LBC may go unnoticed. Later it may present as a thickened area, engorgement, swelling, recently inverted nipples, altered appearance and or texture in the breast. However, invasive lobular carcinoma is less likely to cause a firm or distinct breast mass compared to other variants. Loss of E-cadherin expression is almost exclusively found in lobular breast cancer in comparison to other breast tumors and hence helps in distinguishing lobular breast tumors from others.

E-cadherin mutations are also associated with Blepharo-cheilo-odontic syndrome (characterized by abnormalities of the eyelids, lips, and teeth) and other congenital anomalies like cleft lip and cleft palate. It also seems to be associated with certain types of ovarian, prostate and endometrial cancers.

Asymptomatic individuals with E-CADHERIN mutations should be considered for prophylactic total gastrectomy despite normal endoscopic findings. In contrast, in women at risk for lobular breast cancer, prophylactic mastectomy is not routinely advocated.

  • Diagnostic confirmation of Hereditary diffuse gastric cancer
  • Screening for familial CDH1 mutation to allow for predictive testing in family members
  • Evaluation and diagnosis of lobular breast carcinoma
Any known pathogenic mutation detected would be consistent with a diagnosis of Hereditary diffuse gastric cancer. If a mutation is identified, genetic testing of at-risk family members should be offered.

No reportable variants were identified

Genotyping by Real-Time PCR, Conventional Sequencing, Next Generation Sequencing (NGS).

Whole blood in EDTA.

Stability

  • Room: 3-5 days
  • Refrigerated: 7-14 days
Gastric biopsy, HER2/neu (ERBB2) Gene Amplification, FISH, Gastroesophageal Cancer, Helicobacter pylori Urea Breath Test, Cancer antigen 19-9 (CA19-9).
7-14 Days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login